Donald S. Brooks

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia.